Depomed To Present At Stifel Nicolaus Healthcare Conference
NEWARK, Calif., Sept. 4, 2013 /PRNewswire/ — Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the 2013 Stifel Nicolaus Healthcare Conference at the Four Seasons Hotel in Boston, Massachusetts.
The presentation at the Stifel Nicolaus conference is scheduled for 8:35 am EDT (5:35 am PDT) on Wednesday, September 11, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days on the company’s website.
Depomed, Inc. is a specialty pharmaceutical company with four approved and marketed products. Gralise(®) (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Zipsor(®) (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Glumetza(®) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Gralise and Glumetza and other product candidates are formulated with Depomed’s proven, proprietary Acuform(®) drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.
August J. Moretti
SOURCE Depomed, Inc.